We use cookies for a better user experience. Read our Privacy Policy

I Agree

Ophthalmic Drugs Market

Ophthalmic Drugs Market (Disease Indication - Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders (Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, and Diabetic Retinopathy), Allergy, and Uveitis; Therapeutic Class - Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids), Anti-infective Drugs (Anti-fungal Drugs and Anti-bacterial Drugs), Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, and Combined Medication), Anti-allergy Drugs, and Anti-VEGF Agents; Product Type - Prescription Drugs and Over-the-Counter Drugs; Distribution Channel - Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global Ophthalmic Drugs Market for the historical period 2017–2018 and forecast period 2019–2027, Rising adoption of newly developed therapeutics in ophthalmology, Increasing incidence rates of eye related disorders, Advanced retinal treatment approvals for unmet needs in eye disorders, Significant awareness about the diagnosis and treatment of eye disorders are projected to drive the global Ophthalmic Drugs Market during the forecast period
  • According to the report, the global Ophthalmic Drugs Market was valued at US$ 26.0 Bn in 2018 and is anticipated to expand at a CAGR of 4.1% from 2019 to 2027

To know the scope of our report Get a Sample on Ophthalmic Drugs Market

Rising adoption of newly developed therapeutics in ophthalmology: Key Drivers

  • As the number of FDA approvals for advanced therapeutics is increasing, the rate of adoption of these newly launched drugs is also rising exponentially.
  • In August 29 2016, Shire introduced Xiidra, a lymphocyte function-associated antigen-1 (LFA-1) antagonist, challenging Allergan’s Restasis, and a cyclosporine immunosuppressant. Both drugs are available at the same price level – around US$ 5,000.0 per year
  • Restasis gathered a revenue of US$ 1419.5 Mn in 2016, whereas Xiiadra earned US$ 54.0 Mn in just four months from its introduction. During October 2016, Xiiadra had 9,963 total prescriptions, up by 8.7% than the earlier week, compared to which Restasis prescriptions fell by 1.7% as compared to the prior week, which resulted in increase in Shire’s market share to 13.3% from 12.2% in the prior week.
  • Shire has set the sales target of US $726.0 Mn and US$ 1,140.0 Mn in 2017, and 2018, respectively. It is estimated to overcome Allergan’s market share in dry eye treatment with these statistics
  • A similar trend of significant new drug adoption is anticipated to be followed, and is projected to drive the expansion of the global ophthalmic drugs market

Get a glimpse of the in-depth analysis through our Report Brochure

Increasing incidence rates of eye related disorders Market Growth

  • There is an alarming rise in incidence of eye related diseases, especially in the developed countries, which is anticipated to drive the growth of the ophthalmic drugs market during 2017-2025
  • According to the Prevent Blindness report, the number of people in the U.S., suffering from cataract is expected to increase from 24.4 Mn in 2010, to 30.5 Mn by 2020, and people suffering from diabetic retinopathy in U.S. are projected to increase from 7.7 Mn in 2010 to 9.2 Mn in 2020
  • The patients for open angle glaucoma and AMD in U.S., were 2.7 Mn and 2.1 Mn, respectively, which are projected to increase to 3.3 Mn and 2.5 Mn, respectively, till 2020
  • The increasing patient pool in developing countries as well as developed regions is estimated to propel healthcare spending for eye treatments in each region and drive the growth of the ophthalmic drugs market.

Advanced retinal treatment approvals for unmet needs in eye disorders drive the market

  • Eye diseases such as chronic or recurrent uveitis, optic nerve, neurodegeneration retinitis pigmentosa, retinoblastoma, etc., lack an effective treatment option, and thus are categorized as unmet medical needs within the ophthalmologic diseases space
  • Several new entrants are dedicated to provide specialized treatment methods for eye diseases:
  • On May 18 2017, Spark Therapeutics, Inc. submitted the first and only Biological License Application to the U.S. FDA for the treatment of Leber’s congenital amaurosis by gene therapy
  • On March 25 2015, Regeneron Pharmaceuticals Inc., announced the approval of Eylea, the first VEGF inhibitor approved for dosing on a less than monthly basis for the treatment of diabetic macular edema
  • Severe inflammatory eye diseases, such as uveitis, lacked a solid treatment option earlier to the FDA approval of Humira for the indication of non-infectious intermediate, posterior, and panuveitis in adult patients
  • In June 2016, the U.S. FDA approved the first and only biologic approved drug, Humira, for the treatment of uveitis
  • Such approvals for advanced treatment options for the treatment of unmet medical needs in the field of eye disorders are projected to boost the expansion of the global ophthalmic drugs market

 Non-compliance with treatment to Hamper Market

  • Topical drug delivery methods are widely employed in case of ophthalmic drugs. The success rate of the medication depends upon the patient’s ability to comply with prescribed therapeutic treatment
  • Lack of knowledge, intolerance, misunderstanding, and denial are some reasons behind the non-compliance
  • As per a study published in American Academy of Ophthalmology, the overall non-compliance rate was around 50% for glaucoma, with lack of knowledge, misunderstanding, and denial accounting for more than 70% of the total non-compliance rate
  • Non-compliance with the treatment is not influenced by gender; however, it is dependent on the understanding of the patient about the drug administration method
  • Increasing non-compliance due to lack of knowledge is expected to restrain the expansion of the global ophthalmic drugs market

Side effects associated with ophthalmic drugs hamper the market

  • Abnormal vision, blurred vision, poor focusing ability, dry/irritated eyes, color perception changes, altered pupil size are common side effects associated with ophthalmic drugs
  • Some side effects such as itching of eyes or stinging sensation, allergic reaction, etc., can create serious health hazards, these side effects may restrain the expansion of the global ophthalmic drugs market

Expanding operations in future? To get the perfect launch ask for a custom report 

Global Ophthalmic Drugs Market: Competitive Landscape

  • This report profiles major players in the global Ophthalmic Drugs Market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global Ophthalmic Drugs Market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global Ophthalmic Drugs Market are
    • Aerie Pharmaceuticals, Inc.
    • ALLERGAN
    • Valeant Pharmaceuticals International, Inc.
    • Bayer AG
    • Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Santen Pharmaceutical Co., Ltd.

Global Ophthalmic Drugs Market: Key Developments

Key players in the global Ophthalmic Drugs Market are engaged in regulatory approvals, technologically advancement of products, launch of new products, and collaborative agreements with other companies. These strategies are likely to fuel the growth of the global Ophthalmic Drugs Market. A few expansion strategies adopted by players operating in the global Ophthalmic Drugs Market are:

  • In February 2017, Valeant Pharmaceuticals International, Inc. and EyeGate Pharmaceuticals, Inc. entered into licensing agreement for the research, commercialization and manufacturing of EyeGate II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients. Such licensing and collaboration agreements are anticipated to strengthen the company’s product portfolio during the forecast period.
  • In February 2017, Pfizer Inc. partnered with the Ophthalmological Society of Nigeria (OSN) and the South East Ophthalmologist’s Forum (SEOF) for the glaucoma awareness campaign in five south eastern states of Nigeria. The company is committed to contributing positively to patient care, and aims at reducing the burden of irreversible eye disease like glaucoma.
  • In May 2017, Shire entered into a collaborative agreement with Parion Sciences, Inc. to exclusively develop and commercialize P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the treatment of dry eye disease

The report on the global Ophthalmic Drugs Market discussed individual strategies, followed by company profiles of manufacturers of oral contraceptive pills. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global Ophthalmic Drugs Market.

Global Ophthalmic Drugs Market - Segmentation

Product Type

Prescription Drugs

OTC Drugs

Therapeutic Class

Anti-inflammatory Drugs

  • NSAIDs
  • Steroids

Anti-infective Drugs

  • Anti-fungal Drugs
  • Anti-bacterial Drugs
  • Others

Anti-glaucoma Drugs

  • Alpha Agonist
  • Beta Blockers
  • Prostaglandin Analogs
  • Combined Medication
  • Others

Anti-allergy Drugs

  • Anti-VEGF Agents
  • Others

Disease Indication

Dry Eye

Glaucoma

Infection/ Inflammation

Retinal Disorders

  • Wet AMD
  • Dry AMD
  • Diabetic Retinopathy
  • Others

Allergy

Uveitis

Others

Distribution Channels

Hospital Pharmacies

Online Pharmacies

Independent Pharmacies & Drug Stores

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the anticipated CAGR of the ophthalmic drugs market in the forecast period?

Ophthalmic drugs market is anticipated to grow at a CAGR of 4.1% during the forecast period

Which is the base year calculated in ophthalmic drugs market report?

2019 is the base year calculated in ophthalmic drugs market report

Which region is expected to project highest market share in ophthalmic drugs market?

North America accounted for a major share of the global ophthalmic drugs market

What are the key driving factors for growth of ophthalmic drugs market?

Ophthalmic drugs market is driven by increasing patient pool in developing countries as well as developed regions is estimated to propel healthcare spending for eye treatments in each region and drive the growth of the market

Who are the key players in global ophthalmic drugs market?

Key players in the global ophthalmic drugs market include Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceuticals, Inc., Pfizer Inc., Novartis AG, Bayer AG, Allergan, Inc., and Aerie Pharmaceuticals, Inc

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ophthalmic Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Ophthalmic Drugs Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Regulatory Scenario, by Region/Globally

    5.2. Pipeline Analysis

    5.3. Disease Prevalence & Incidence Rate globally with key countries

6. Global Ophthalmic Drugs Market Analysis and Forecasts, By Product

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast By Product, 2017–2027

        6.3.1. Prescription Drugs

        6.3.2. OTC Drugs

    6.4. Market Attractiveness By Product

7. Global Ophthalmic Drugs Market Analysis and Forecasts, By Therapeutic Class

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast By Therapeutic Class, 2017–2027

        7.3.1. Anti-inflammatory Drugs

            7.3.1.1. NSAIDs

            7.3.1.2. Steroids

        7.3.2. Anti-infective Drugs

            7.3.2.1. Anti-fungal Drugs

            7.3.2.2. Anti-bacterial Drugs

            7.3.2.3. Others

        7.3.3. Anti-glaucoma Drugs

            7.3.3.1. Alpha Agonist

            7.3.3.2. Beta Blockers

            7.3.3.3. Prostaglandin Analogs

            7.3.3.4. Combined Medication

            7.3.3.5. Others

        7.3.4. Anti-allergy Drugs

        7.3.5. Anti-VEGF Agents

        7.3.6. Others

    7.4. Market Attractiveness By Therapeutic Class

8. Global Ophthalmic Drugs Market Analysis and Forecasts, By Disease Indication

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast By Disease Indication, 2017–2027

        8.3.1. Dry Eye

        8.3.2. Glaucoma

        8.3.3. Infection/Inflammation

        8.3.4. Retinal Disorders

            8.3.4.1. Wet AMD

            8.3.4.2. Dry AMD

            8.3.4.3. Diabetic Retinopathy

            8.3.4.4. Others

        8.3.5. Allergy

        8.3.6. Uveitis

        8.3.7. Others

    8.4. Market Attractiveness By Disease Indication

9. Global Ophthalmic Drugs Market Analysis and Forecasts, By Distribution Channels

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast By Distribution Channels, 2017–2027

        9.3.1. Hospital Pharmacies

        9.3.2. Online Pharmacies

        9.3.3. Independent Pharmacies & Drug Stores

    9.4. Market Attractiveness By Distribution Channels

10. Global Ophthalmic Drugs Market Analysis and Forecasts, By Region

    10.1. Key Findings

    10.2. Market Value Forecast By Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. Latin America 

        10.2.5. Middle East & Africa 

    10.3. Market Attractiveness By Country/Region

11. North America Ophthalmic Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast By Product, 2017–2027

        11.2.1. Prescription Drugs

        11.2.2. OTC Drugs

    11.3. Market Value Forecast By Therapeutic Class, 2017–2027

        11.3.1. Anti-inflammatory Drugs

            11.3.1.1. NSAIDs

            11.3.1.2. Steroids

        11.3.2. Anti-infective Drugs

            11.3.2.1. Anti-fungal Drugs

            11.3.2.2. Anti-bacterial Drugs

            11.3.2.3. Others

        11.3.3. Anti-glaucoma Drugs

            11.3.3.1. Alpha Agonist

            11.3.3.2. Beta Blockers

            11.3.3.3. Prostaglandin Analogs

            11.3.3.4. Combined Medication

            11.3.3.5. Others

        11.3.4. Anti-allergy Drugs

        11.3.5. Anti-VEGF Agents

        11.3.6. Others

    11.4. Market Value Forecast By Disease Indication, 2017–2027

        11.4.1. Dry Eye

        11.4.2. Glaucoma

        11.4.3. Infection/Inflammation

        11.4.4. Retinal Disorders

            11.4.4.1. Wet AMD

            11.4.4.2. Dry AMD

            11.4.4.3. Diabetic Retinopathy

            11.4.4.4. Others

        11.4.5. Allergy

        11.4.6. Uveitis

        11.4.7. Others

    11.5. Market Value Forecast By Distribution Channels, 2017–2027

        11.5.1. Hospital Pharmacies

        11.5.2. Online Pharmacies

        11.5.3. Independent Pharmacies & Drug Stores

    11.6. Market Value Forecast By Country, 2017–2027

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis 

        11.7.1. By Product

        11.7.2. By Therapeutic Class

        11.7.3. By Disease Indication

        11.7.4. By Distribution Channels

        11.7.5. By Country

12. Europe Ophthalmic Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast By Product, 2017–2027

        12.2.1. Prescription Drugs

        12.2.2. OTC Drugs

    12.3. Market Value Forecast By Therapeutic Class, 2017–2027

        12.3.1. Anti-inflammatory Drugs

            12.3.1.1. NSAIDs

            12.3.1.2. Steroids

        12.3.2. Anti-infective Drugs

            12.3.2.1. Anti-fungal Drugs

            12.3.2.2. Anti-bacterial Drugs

            12.3.2.3. Others

        12.3.3. Anti-glaucoma Drugs

            12.3.3.1. Alpha Agonist

            12.3.3.2. Beta Blockers

            12.3.3.3. Prostaglandin Analogs

            12.3.3.4. Combined Medication

            12.3.3.5. Others

        12.3.4. Anti-allergy Drugs

        12.3.5. Anti-VEGF Agents

        12.3.6. Others

    12.4. Market Value Forecast By Disease Indication, 2017–2027

        12.4.1. Dry Eye

        12.4.2. Glaucoma

        12.4.3. Infection/Inflammation

        12.4.4. Retinal Disorders

            12.4.4.1. Wet AMD

            12.4.4.2. Dry AMD

            12.4.4.3. Diabetic Retinopathy

            12.4.4.4. Others

        12.4.5. Allergy

        12.4.6. Uveitis

        12.4.7. Others

    12.5. Market Value Forecast By Distribution Channels, 2017–2027

        12.5.1. Hospital Pharmacies

        12.5.2. Online Pharmacies

        12.5.3. Independent Pharmacies & Drug Stores

    12.6. Market Value Forecast By Country, 2017–2027

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis 

        12.7.1. By Product

        12.7.2. By Therapeutic Class

        12.7.3. By Disease Indication

        12.7.4. By Distribution Channels

        12.7.5. By Country

13. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast By Product, 2017–2027

        13.2.1. Prescription Drugs

        13.2.2. OTC Drugs

    13.3. Market Value Forecast By Therapeutic Class, 2017–2027

        13.3.1. Anti-inflammatory Drugs

            13.3.1.1. NSAIDs

            13.3.1.2. Steroids

        13.3.2. Anti-infective Drugs

            13.3.2.1. Anti-fungal Drugs

            13.3.2.2. Anti-bacterial Drugs

            13.3.2.3. Others

        13.3.3. Anti-glaucoma Drugs

            13.3.3.1. Alpha Agonist

            13.3.3.2. Beta Blockers

            13.3.3.3. Prostaglandin Analogs

            13.3.3.4. Combined Medication

            13.3.3.5. Others

        13.3.4. Anti-allergy Drugs

        13.3.5. Anti-VEGF Agents

        13.3.6. Others

    13.4. Market Value Forecast By Disease Indication, 2017–2027

        13.4.1. Dry Eye

        13.4.2. Glaucoma

        13.4.3. Infection/Inflammation

        13.4.4. Retinal Disorders

            13.4.4.1. Wet AMD

            13.4.4.2. Dry AMD

            13.4.4.3. Diabetic Retinopathy

            13.4.4.4. Others

        13.4.5. Allergy

        13.4.6. Uveitis

        13.4.7. Others

    13.5. Market Value Forecast By Distribution Channels, 2017–2027

        13.5.1. Hospital Pharmacies

        13.5.2. Online Pharmacies

        13.5.3. Independent Pharmacies & Drug Stores

    13.6. Market Value Forecast By Country, 2017–2027

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis 

        13.7.1. By Product

        13.7.2. By Therapeutic Class

        13.7.3. By Disease Indication

        13.7.4. By Distribution Channels

        13.7.5. By Country

14. Latin America Ophthalmic Drugs Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast By Product, 2017–2027

        14.2.1. Prescription Drugs

        14.2.2. OTC Drugs

    14.3. Market Value Forecast By Therapeutic Class, 2017–2027

        14.3.1. Anti-inflammatory Drugs

            14.3.1.1. NSAIDs

            14.3.1.2. Steroids

        14.3.2. Anti-infective Drugs

            14.3.2.1. Anti-fungal Drugs

            14.3.2.2. Anti-bacterial Drugs

            14.3.2.3. Others

        14.3.3. Anti-glaucoma Drugs

            14.3.3.1. Alpha Agonist

            14.3.3.2. Beta Blockers

            14.3.3.3. Prostaglandin Analogs

            14.3.3.4. Combined Medication

            14.3.3.5. Others

        14.3.4. Anti-allergy Drugs

        14.3.5. Anti-VEGF Agents

        14.3.6. Others

    14.4. Market Value Forecast By Disease Indication, 2017–2027

        14.4.1. Dry Eye

        14.4.2. Glaucoma

        14.4.3. Infection/Inflammation

        14.4.4. Retinal Disorders

            14.4.4.1. Wet AMD

            14.4.4.2. Dry AMD

            14.4.4.3. Diabetic Retinopathy

            14.4.4.4. Others

        14.4.5. Allergy

        14.4.6. Uveitis

        14.4.7. Others

    14.5. Market Value Forecast By Distribution Channels, 2017–2027

        14.5.1. Hospital Pharmacies

        14.5.2. Online Pharmacies

        14.5.3. Independent Pharmacies & Drug Stores

    14.6. Market Value Forecast By Country, 2017–2027

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis 

        14.7.1. By Product

        14.7.2. By Therapeutic Class

        14.7.3. By Disease Indication

        14.7.4. By Distribution Channels

        14.7.5. By Country

15. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast By Product, 2017–2027

        15.2.1. Prescription Drugs

        15.2.2. OTC Drugs

    15.3. Market Value Forecast By Therapeutic Class, 2017–2027

        15.3.1. Anti-inflammatory Drugs

            15.3.1.1. NSAIDs

            15.3.1.2. Steroids

        15.3.2. Anti-infective Drugs

            15.3.2.1. Anti-fungal Drugs

            15.3.2.2. Anti-bacterial Drugs

            15.3.2.3. Others

        15.3.3. Anti-glaucoma Drugs

            15.3.3.1. Alpha Agonist

            15.3.3.2. Beta Blockers

            15.3.3.3. Prostaglandin Analogs

            15.3.3.4. Combined Medication

            15.3.3.5. Others

        15.3.4. Anti-allergy Drugs

        15.3.5. Anti-VEGF Agents

        15.3.6. Others

    15.4. Market Value Forecast By Disease Indication, 2017–2027

        15.4.1. Dry Eye

        15.4.2. Glaucoma

        15.4.3. Infection/Inflammation

        15.4.4. Retinal Disorders

            15.4.4.1. Wet AMD

            15.4.4.2. Dry AMD

            15.4.4.3. Diabetic Retinopathy

            15.4.4.4. Others

        15.4.5. Allergy

        15.4.6. Uveitis

        15.4.7. Others

    15.5. Market Value Forecast By Distribution Channels, 2017–2027

        15.5.1. Hospital Pharmacies

        15.5.2. Online Pharmacies

        15.5.3. Independent Pharmacies & Drug Stores

    15.6. Market Value Forecast By Country, 2017–2027

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis 

        15.7.1. By Product

        15.7.2. By Therapeutic Class

        15.7.3. By Disease Indication

        15.7.4. By Distribution Channels

        15.7.5. By Country

16. Competition Landscape

    16.1. Market Player – Competition Matrix (By Tier and Size of companies)

    16.2. Market Share Analysis By Company (2018)

    16.3. Company Profiles

        16.3.1. Aerie Pharmaceuticals, Inc.

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Growth Strategies

            16.3.1.3. SWOT Analysis

        16.3.2. ALLERGAN

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Growth Strategies

            16.3.2.3. SWOT Analysis

        16.3.3. Valeant Pharmaceuticals International, Inc.

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Growth Strategies

            16.3.3.3. SWOT Analysis

        16.3.4. Bayer AG

            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.4.2. Growth Strategies

            16.3.4.3. SWOT Analysis

        16.3.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Growth Strategies

            16.3.5.3. SWOT Analysis

        16.3.6. Novartis AG

            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.6.2. Growth Strategies

            16.3.6.3. SWOT Analysis

        16.3.7. Pfizer Inc.

            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.7.2. Growth Strategies

            16.3.7.3. SWOT Analysis

        16.3.8. Regeneron Pharmaceuticals, Inc.

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Growth Strategies

            16.3.8.3. SWOT Analysis

        16.3.9. Santen Pharmaceutical Co., Ltd.

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Growth Strategies

            16.3.9.3. SWOT Analysis

        16.3.10. Actavis Generics (Teva Pharmaceutical Industries Ltd.)

            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.10.2. Growth Strategies

            16.3.10.3. SWOT Analysis

        16.3.11. Other Prominent Key Players

List of Tables

Table 01: Product Offering - Major Market Players

Table 02: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 03: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2017–2027

Table 04: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 05: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2017–2027

Table 06: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2017–2027

Table 07: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2017–2027

Table 08: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 09: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 10: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 11: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 12: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 13: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2017–2027

Table 14: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 15: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2017–2027

Table 16: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2017–2027

Table 17: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2017–2027

Table 18: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 19: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2027

Table 20: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2027

Table 21: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 22: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2017–2027

Table 23: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 24: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drug, 2017–2027

Table 25: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drug, 2017–2027

Table 26: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drug, 2017–2027

Table 27: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 28: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 29: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 30: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 31: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2017–2027

Table 32: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 33: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2017–2027

Table 34: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2017–2027

Table 35: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2017–2027

Table 36: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 37: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 38: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 39: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 40: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2017–2027

Table 41: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 42: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2017–2027

Table 43: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2017–2027

Table 44: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2017–2027

Table 45: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 46: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 47: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2027

Table 48: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 49: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication - Retinal Disorder, 2017–2027

Table 50: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 51: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2017–2027

Table 52: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2017–2027

Table 53: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2017–2027

Table 54: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 55: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figure

Figure 01: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017–2027

Figure 02: Global Company Share: Anti-glaucoma Drugs, 2018

Figure 03: Analysis of Global Causes of Blindness (%)

Figure 04: Analysis of U.S. Causes of Blindness (%)

Figure 05: Analysis of Europe - Causes of Blindness (%)

Figure 06: Analysis of Japan Causes of Blindness (%)

Figure 07: Global Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2019–2027

Figure 08: Global Ophthalmic Drugs Market Value Share, by Disease Indication, 2018 and 2027

Figure 09: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Dry Eye, 2017–2027

Figure 10: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Glaucoma, 2017–2027

Figure 11: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Infection/Inflammation, 2017–2027

Figure 12: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Retinal Disorders, 2017–2027

Figure 13: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Uveitis, 2017–2027

Figure 14: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Allergy, 2017–2027

Figure 15: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Other Ophthalmic Diseases, 2017–2027

Figure 16: Global Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 17: Global Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2018 and 2027

Figure 19: Global Ophthalmic Drugs Market, by Anti-infective Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2027

Figure 18: Global Ophthalmic Drugs Market, by Anti-inflammatory Drugs Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2027

Figure 20: Global Ophthalmic Drugs Market, by Anti-glaucoma Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2027

Figure 21: Global Ophthalmic Drugs Market, by Anti-VEGF Agents, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2027

Figure 22: Global Ophthalmic Drugs Market, by Anti-allergy Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2027

Figure 23: Global Ophthalmic Drugs Market, by Others Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2027

Figure 24: Global Ophthalmic Drugs Market Value Share, by Product Type, for 2018 and 2027

Figure 25: Global Ophthalmic Drugs Market Attractiveness, by Product Type, 2019–2027

Figure 26: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Prescription Drugs, 2017–2027

Figure 27: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by OTC Drugs, 2017–2027

Figure 28: Global Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2018 and 2027

Figure 29: Global Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2019–2027

Figure 30: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Online Pharmacies, 2017–2027

Figure 31: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Hospital Pharmacies, 2017–2027

Figure 32: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Independent Pharmacies & Drug Stores, 2017–2027

Figure 33: Global Ophthalmic Drugs Market Value Share, by Region, for 2018 and 2027 

Figure 34: Global Ophthalmic Drugs Market Attractiveness, by Region, 2019–2027

Figure 35: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 36: North America Ophthalmic Drugs Market Attractiveness, by Country, 2019–2027

Figure 37: North America Ophthalmic Drugs Market Value Share, by Country, 2018 and 2027

Figure 38: North America Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2017–2027

Figure 39: North America Ophthalmic Drugs Market Value Share, by Disease Indication, 2018 and 2027

Figure 40: North America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2018 and 2027

Figure 41: North America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 42: North America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2018 and 2027

Figure 43: North America Ophthalmic Drugs Market Attractiveness, by Product Type, 2019–2027

Figure 44: North America Ophthalmic Drugs Market Value Share, by Distribution Channels, 2018 and 2027

Figure 45: North America Ophthalmic Drugs Market Attractiveness, by Distribution Channels, 2019–2027

Figure 46: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 47: Europe Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2019–2027

Figure 48: Europe Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2018 and 2027

Figure 49: Europe Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2015-2025

Figure 50: Europe Ophthalmic Drugs Market Value Share, by Disease Indication, 2018 and 2027

Figure 51: Europe Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2018 and 2027

Figure 52: Europe Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 53: Europe Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2018 and 2027

Figure 54: Europe Ophthalmic Drugs Market Attractiveness, by Product Type, 2019–2027

Figure 55: Europe Ophthalmic Drugs Market Value Share, by Distribution Channel, 2018 and 2027

Figure 56: Europe Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2019–2027

Figure 57: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 58: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 59: Asia Pacific Ophthalmic Drugs Market Value Share, by Country/Sub-region, for 2018 and 2027

Figure 60: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017–2027

Figure 61: Asia Pacific Ophthalmic Drugs Market Value Share, by Disease Indication, for 2018 and 2027

Figure 62: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 63: Asia Pacific Ophthalmic Drugs Market Value Share, by Therapeutic Class, for 2018 and 2027

Figure 64: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Product Type, for 2018 and 2027

Figure 65: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Product Type, 2019–2027

Figure 66: Asia Pacific Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2018 and 2027

Figure 67: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2019–2027

Figure 68: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 69: Latin America Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 70: Latin America Ophthalmic Drugs Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 71: Latin America Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017–2027

Figure 72: Latin America Ophthalmic Drugs Market Value Share, by Disease Indication, 2018 and 2027

Figure 73: Latin America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 74: Latin America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2018 and 2027

Figure 75: Latin America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2018 and 2027

Figure 76: Latin America Ophthalmic Drugs Market Attractiveness, by Product Type, 2019–2027

Figure 77: Latin America Ophthalmic Drugs Market Value Share, by Distribution Channel, 2018 and 2027

Figure 78: Latin America Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2019–2027

Figure 79: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 80: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2019–2027

Figure 81: Middle East & Africa Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2018 and 2027

Figure 82: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2019–2027

Figure 83: Middle East & Africa Ophthalmic Drugs Market Value Share, by Disease Indication, 2018 and 2027

Figure 84: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 85: Middle East & Africa Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2018 and 2027

Figure 86: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2018 and 2027

Figure 87: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Product Type, 2019–2027

Figure 88: Middle East & Africa Ophthalmic Drugs Market Value Share, by Distribution Channel, 2018 and 2027

Figure 89: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2019–2027

Figure 90: Global Ophthalmic Drugs Market Share, by Company, 2018

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved